Hapvida Participacoes e Investimentos SA
OTC:HAPVY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hapvida Participacoes e Investimentos SA
OTC:HAPVY
|
BR |
|
Bioxyne Ltd
ASX:BLS
|
AU |
|
A
|
ASM International NV
XHAN:AVS
|
NL |
|
Conico Ltd
F:BDD
|
AU |
|
POWR Lithium Corp
F:6JX
|
CA |
|
D
|
Discovery Silver Corp
OTC:DSVSF
|
CA |
|
G
|
Goldex Resources Corp
XTSX:GDX
|
CA |
|
A
|
Azgard Nine Ltd
KAR:ANL
|
PK |
|
P
|
Petrolimex Ha Noi Transportation and Trading JSC
VN:PJC
|
VN |
|
K
|
Koala Company Ltd
ASX:KOA
|
AU |
|
Hapvida Participacoes e Investimentos SA
BOVESPA:HAPV3
|
BR |
|
I
|
Inpro SA
WSE:INP
|
PL |
|
S
|
Song Da No5 JSC
VN:SD5
|
VN |
|
Duro Felguera SA
F:DF5B
|
ES |
Hapvida Participacoes e Investimentos SA
Hapvida is a Brazilian healthcare company that sells health insurance plans and also runs its own network of hospitals, clinics, emergency rooms, and diagnostic centers. It is not just an insurer or just a hospital chain; it combines both, which lets it control more of the patient journey from plan enrollment to treatment and testing. Its main customers are individuals and companies that buy medical coverage for employees, along with people who use its dental plans and private healthcare network. Hapvida makes money mainly by collecting monthly premiums from health plan members and by charging for medical and dental services inside its own network. Because it owns much of the care delivery system, it can keep more of the spending within the company instead of paying outside providers for everything. That integrated model is what sets Hapvida apart. In the Brazilian healthcare market, it acts as both payer and provider, which gives it direct exposure to insurance risk and clinical operations at the same time. This makes the business easier to understand as a combined membership-and-care platform rather than a pure insurer or a pure hospital operator.
Hapvida is a Brazilian healthcare company that sells health insurance plans and also runs its own network of hospitals, clinics, emergency rooms, and diagnostic centers. It is not just an insurer or just a hospital chain; it combines both, which lets it control more of the patient journey from plan enrollment to treatment and testing.
Its main customers are individuals and companies that buy medical coverage for employees, along with people who use its dental plans and private healthcare network. Hapvida makes money mainly by collecting monthly premiums from health plan members and by charging for medical and dental services inside its own network. Because it owns much of the care delivery system, it can keep more of the spending within the company instead of paying outside providers for everything.
That integrated model is what sets Hapvida apart. In the Brazilian healthcare market, it acts as both payer and provider, which gives it direct exposure to insurance risk and clinical operations at the same time. This makes the business easier to understand as a combined membership-and-care platform rather than a pure insurer or a pure hospital operator.
Results: Hapvida said Q2 results were still pressured, with net revenue of nearly BRL 8.0 billion, adjusted EBITDA of BRL 504 million and net income of BRL 12 million.
Portfolio cleanup: Management is tightening contract profitability rules and said about 10% of members were under stricter review in June; in July, about 50,000 members were canceled and 10,000 renewed on improved terms.
Litigation pressure: Civil litigation, judicial claims and duplicate blocks weighed on the quarter, but management said the legal process is being redesigned and should start improving in Q4.
Margin focus: The company is shifting from growth at any cost to margin recovery, cash generation and deleveraging, including contract renegotiations, network rationalization and procurement savings.
Cash and debt: Net debt was BRL 5.4 billion in June 2026 versus BRL 5.2 billion in December 2025, excluding about BRL 170 million of M&A effects it was roughly flat.
Outlook: Management expects quarter 3 to be more normal seasonally, with further benefits from pricing, contract cleanup and cost actions starting to show more clearly in the next quarters.